Speaker: Marc Schauer

Mr. Marc Philipp Schauer is studying human medicine and law at the University of Würzburg. In addition to research and study stays at the University of Birmingham and the Stanford University School of Medicine, Mr. Schauer has worked as part of his doctoral thesis at the University Hospital of Würzburg (Prof. Martin Fassnacht & Prof. Michael Hudecek), where he developed and preclinically evaluated the world's first CAR-T cell therapy for the treatment of adrenocortical carcinoma (ACC), which is going to be tested in ACC patients in 2024. His work, which was awarded the Schöller-Junkmann Prize - the most highly endowed prize of the German Society of Endocrinology - at the beginning of 2024, shows how CRISPR/Cas9-edited CAR-T cells without glucocorticoid receptor are able to curatively treat GC-producing ACC tumors in vitro and in vivo. He is currently working as a research fellow in the field of Endocrine Oncology at the University Hospital Würzburg, where he is focussing his research on the further and new development of CAR-T cell therapies for the treatment of ACC.